JP2018515581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515581A5 JP2018515581A5 JP2017561259A JP2017561259A JP2018515581A5 JP 2018515581 A5 JP2018515581 A5 JP 2018515581A5 JP 2017561259 A JP2017561259 A JP 2017561259A JP 2017561259 A JP2017561259 A JP 2017561259A JP 2018515581 A5 JP2018515581 A5 JP 2018515581A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- amino
- pyridinyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 106
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- 125000001153 fluoro group Chemical group F* 0.000 claims description 36
- 125000004076 pyridyl group Chemical group 0.000 claims description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims description 21
- -1 5-methyl -1H- pyrazole-3 -yl Chemical group 0.000 claims description 20
- 239000012453 solvate Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 11
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 239000002002 slurry Substances 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- AASNOMRPOYJIIP-GNEAJKGCSA-N 2-(dimethylamino)-1-[(1R,5S)-3-[[7-[(5-methylpyrazolidin-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-9-azabicyclo[3.3.1]nonan-9-yl]ethanone Chemical compound CC1CC(Nc2cc3ncccc3c(NC3C[C@@H]4CCC[C@H](C3)N4C(=O)CN(C)C)n2)NN1 AASNOMRPOYJIIP-GNEAJKGCSA-N 0.000 claims description 2
- JWKYPPQDMJUMOS-VYHVNNPOSA-N 2-methylpropyl (1R,5S)-3-[[2-(hydroxymethyl)-7-[(5-methylpyrazolidin-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)COC(=O)N1[C@H]2CC[C@@H]1CC(C2)Nc1nc(NC2CC(C)NN2)cc2nc(CO)ccc12 JWKYPPQDMJUMOS-VYHVNNPOSA-N 0.000 claims description 2
- YVVUBTBQIVSPDN-QFPZOOBNSA-N 5-N-[(1R,5S)-8-(2-fluoroethyl)-8-azabicyclo[3.2.1]octan-3-yl]-7-N-(5-methylpyrazolidin-3-yl)-1,6-naphthyridine-5,7-diamine Chemical compound CC1CC(Nc2cc3ncccc3c(NC3C[C@@H]4CC[C@H](C3)N4CCF)n2)NN1 YVVUBTBQIVSPDN-QFPZOOBNSA-N 0.000 claims description 2
- AZVVKKGVTCXYMH-SEBLRQCZSA-N 5-N-[(1R,5S)-8-(2-methoxyethylsulfonyl)-8-azabicyclo[3.2.1]octan-3-yl]-7-N-(5-methylpyrazolidin-3-yl)-1,6-naphthyridine-5,7-diamine Chemical compound COCCS(=O)(=O)N1[C@H]2CC[C@@H]1CC(C2)Nc1nc(NC2CC(C)NN2)cc2ncccc12 AZVVKKGVTCXYMH-SEBLRQCZSA-N 0.000 claims description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims 12
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 208000036379 Sigmoiditis Diseases 0.000 claims 3
- 208000014965 pancolitis Diseases 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010056979 Colitis microscopic Diseases 0.000 claims 2
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 2
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036774 Proctitis Diseases 0.000 claims 2
- 206010036783 Proctitis ulcerative Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000008609 collagenous colitis Diseases 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000009326 ileitis Diseases 0.000 claims 2
- 208000027139 infectious colitis Diseases 0.000 claims 2
- 208000004341 lymphocytic colitis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N CC(CO1)OC1=O Chemical compound CC(CO1)OC1=O RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- DIJBVDNZHHSFOY-UHFFFAOYSA-N CC(C)C(CCO1)C1=O Chemical compound CC(C)C(CCO1)C1=O DIJBVDNZHHSFOY-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- QRMNTRLOZPNTCG-SEBLRQCZSA-N N-methyl-2-[(1S,5R)-3-[[7-[(5-methylpyrazolidin-3-yl)amino]-1,6-naphthyridin-5-yl]amino]-9-azabicyclo[3.3.1]nonan-9-yl]acetamide Chemical compound CNC(=O)CN1[C@H]2CCC[C@@H]1CC(C2)Nc1nc(NC2CC(C)NN2)cc2ncccc12 QRMNTRLOZPNTCG-SEBLRQCZSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007613 slurry method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167694P | 2015-05-28 | 2015-05-28 | |
| US62/167,694 | 2015-05-28 | ||
| US201662312273P | 2016-03-23 | 2016-03-23 | |
| US62/312,273 | 2016-03-23 | ||
| PCT/US2016/034243 WO2016191524A1 (en) | 2015-05-28 | 2016-05-26 | Naphthyridine compounds as jak kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020049467A Division JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515581A JP2018515581A (ja) | 2018-06-14 |
| JP2018515581A5 true JP2018515581A5 (https=) | 2019-05-09 |
| JP6692836B2 JP6692836B2 (ja) | 2020-05-13 |
Family
ID=56118022
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017561259A Active JP6692836B2 (ja) | 2015-05-28 | 2016-05-26 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020049467A Active JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020155460A Active JP6942853B2 (ja) | 2015-05-28 | 2020-09-16 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2021047526A Withdrawn JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020049467A Active JP6850922B2 (ja) | 2015-05-28 | 2020-03-19 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2020155460A Active JP6942853B2 (ja) | 2015-05-28 | 2020-09-16 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| JP2021047526A Withdrawn JP2021098757A (ja) | 2015-05-28 | 2021-03-22 | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9725470B2 (https=) |
| EP (2) | EP3303348B1 (https=) |
| JP (4) | JP6692836B2 (https=) |
| KR (1) | KR20180011272A (https=) |
| CN (2) | CN111362975B (https=) |
| AU (2) | AU2016267141B2 (https=) |
| BR (1) | BR112017025542A2 (https=) |
| CA (1) | CA2983453A1 (https=) |
| CL (1) | CL2017002994A1 (https=) |
| CO (1) | CO2017012267A2 (https=) |
| CY (1) | CY1122279T1 (https=) |
| DK (1) | DK3303348T3 (https=) |
| EA (1) | EA032953B1 (https=) |
| ES (2) | ES2753159T3 (https=) |
| HU (1) | HUE046130T2 (https=) |
| IL (3) | IL255358B (https=) |
| LT (1) | LT3303348T (https=) |
| ME (1) | ME03610B (https=) |
| MX (2) | MX378963B (https=) |
| PH (1) | PH12017502050B1 (https=) |
| PL (1) | PL3303348T3 (https=) |
| PT (1) | PT3303348T (https=) |
| RS (1) | RS59522B1 (https=) |
| SA (1) | SA517390337B1 (https=) |
| SG (1) | SG10201910742VA (https=) |
| SI (1) | SI3303348T1 (https=) |
| SM (1) | SMT201900587T1 (https=) |
| TW (2) | TWI704152B (https=) |
| UA (1) | UA121138C2 (https=) |
| WO (1) | WO2016191524A1 (https=) |
| ZA (1) | ZA201707326B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6692836B2 (ja) | 2015-05-28 | 2020-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| US10556901B2 (en) | 2015-11-03 | 2020-02-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors |
| EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| MX377180B (es) | 2016-04-28 | 2025-03-07 | Theravance Biopharma R&D Ip Llc | Compuestos de pirimidina como inhibidores de la quinasa jak. |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| HRP20221221T1 (hr) * | 2017-10-27 | 2022-12-09 | Theravance Biopharma R&D Ip, Llc | Pirimidinski spoj kao inhibitor jak kinaze |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2020108516A1 (zh) * | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| JP2022510980A (ja) * | 2018-11-30 | 2022-01-28 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ヘテロ芳香族誘導体調節因子、その製造方法及び使用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TW202106681A (zh) * | 2019-04-24 | 2021-02-16 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 用於治療皮膚疾病之嘧啶jak抑制劑 |
| EP3958969B1 (en) * | 2019-04-24 | 2024-01-10 | Theravance Biopharma R&D IP, LLC | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113717202B (zh) * | 2020-05-25 | 2025-10-17 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的自由碱晶型及其制备方法 |
| WO2021238908A1 (zh) * | 2020-05-25 | 2021-12-02 | 上海翰森生物医药科技有限公司 | 杂芳类衍生物的盐、晶型及其制备方法 |
| WO2022076703A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Processes for preparing a pan-jak inhibitor and related intermediate compounds |
| WO2022076714A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solid forms of a pan-jak inhibitor |
| WO2022076709A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Formulation of a pan-jak inhibitor |
| WO2022076717A1 (en) | 2020-10-09 | 2022-04-14 | Janssen Biotech, Inc. | Solvate forms of a pan-jak inhibitor |
| US20240158392A1 (en) * | 2021-02-01 | 2024-05-16 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| BR112023018286A2 (pt) | 2021-03-11 | 2023-10-31 | Janssen Pharmaceutica Nv | Lorpucitinib para uso no tratamento de distúrbios mediados por jak |
| WO2022241188A1 (en) | 2021-05-14 | 2022-11-17 | Theravance Biopharma R&D Ip, Llc | Enantioselective synthesis of aminotropane compound |
| WO2023011359A1 (zh) * | 2021-08-05 | 2023-02-09 | 南京明德新药研发有限公司 | 桥环类化合物及其应用 |
| WO2023102800A1 (en) | 2021-12-09 | 2023-06-15 | Theravance Biopharma R&D Ip, Llc | Synthesis of 5, 7-dichloro-1, 6-naphthyridine |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
| KR20250042155A (ko) | 2022-07-27 | 2025-03-26 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 축합 고리계 화합물, 이의 제조 방법 및 이의 의학적 응용 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| NZ526472A (en) | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| EP1595881A1 (en) * | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
| US20110269740A1 (en) * | 2008-07-02 | 2011-11-03 | Ambit Biosciences Corporation | Jak kinase modulating compounds and methods of use thereof |
| JP2011529932A (ja) * | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| CN102227422A (zh) | 2008-09-30 | 2011-10-26 | 阿斯利康(瑞典)有限公司 | 杂环jak激酶抑制剂 |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| EP2527344A1 (en) * | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| CN105367555B (zh) | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| JP6692836B2 (ja) | 2015-05-28 | 2020-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物 |
| MX377180B (es) | 2016-04-28 | 2025-03-07 | Theravance Biopharma R&D Ip Llc | Compuestos de pirimidina como inhibidores de la quinasa jak. |
-
2016
- 2016-05-26 JP JP2017561259A patent/JP6692836B2/ja active Active
- 2016-05-26 KR KR1020177037794A patent/KR20180011272A/ko not_active Ceased
- 2016-05-26 EP EP16728495.9A patent/EP3303348B1/en active Active
- 2016-05-26 EA EA201792619A patent/EA032953B1/ru unknown
- 2016-05-26 DK DK16728495T patent/DK3303348T3/da active
- 2016-05-26 PT PT167284959T patent/PT3303348T/pt unknown
- 2016-05-26 US US15/165,126 patent/US9725470B2/en active Active
- 2016-05-26 MX MX2017015211A patent/MX378963B/es unknown
- 2016-05-26 ME MEP-2019-289A patent/ME03610B/me unknown
- 2016-05-26 LT LT16728495T patent/LT3303348T/lt unknown
- 2016-05-26 MX MX2020011774A patent/MX383074B/es unknown
- 2016-05-26 AU AU2016267141A patent/AU2016267141B2/en not_active Ceased
- 2016-05-26 SI SI201630490T patent/SI3303348T1/sl unknown
- 2016-05-26 PL PL16728495T patent/PL3303348T3/pl unknown
- 2016-05-26 UA UAA201712873A patent/UA121138C2/uk unknown
- 2016-05-26 EP EP19182836.7A patent/EP3569604B1/en active Active
- 2016-05-26 ES ES16728495T patent/ES2753159T3/es active Active
- 2016-05-26 CN CN202010325911.7A patent/CN111362975B/zh active Active
- 2016-05-26 WO PCT/US2016/034243 patent/WO2016191524A1/en not_active Ceased
- 2016-05-26 SM SM20190587T patent/SMT201900587T1/it unknown
- 2016-05-26 BR BR112017025542-1A patent/BR112017025542A2/pt active Search and Examination
- 2016-05-26 SG SG10201910742VA patent/SG10201910742VA/en unknown
- 2016-05-26 CA CA2983453A patent/CA2983453A1/en not_active Abandoned
- 2016-05-26 RS RS20191390A patent/RS59522B1/sr unknown
- 2016-05-26 HU HUE16728495A patent/HUE046130T2/hu unknown
- 2016-05-26 CN CN201680029912.9A patent/CN107667108B/zh active Active
- 2016-05-26 ES ES19182836T patent/ES2924698T3/es active Active
- 2016-05-27 TW TW105116751A patent/TWI704152B/zh not_active IP Right Cessation
- 2016-05-27 TW TW109132390A patent/TWI746178B/zh not_active IP Right Cessation
-
2017
- 2017-06-23 US US15/631,220 patent/US10072026B2/en active Active
- 2017-10-27 ZA ZA2017/07326A patent/ZA201707326B/en unknown
- 2017-10-31 IL IL255358A patent/IL255358B/en active IP Right Grant
- 2017-11-09 PH PH12017502050A patent/PH12017502050B1/en unknown
- 2017-11-14 SA SA517390337A patent/SA517390337B1/ar unknown
- 2017-11-27 CL CL2017002994A patent/CL2017002994A1/es unknown
- 2017-11-29 CO CONC2017/0012267A patent/CO2017012267A2/es unknown
-
2018
- 2018-08-06 US US16/055,386 patent/US10494382B2/en active Active
-
2019
- 2019-10-11 US US16/599,434 patent/US10947254B2/en active Active
- 2019-11-06 CY CY20191101165T patent/CY1122279T1/el unknown
-
2020
- 2020-01-15 IL IL272057A patent/IL272057B/en active IP Right Grant
- 2020-03-19 JP JP2020049467A patent/JP6850922B2/ja active Active
- 2020-03-27 AU AU2020202181A patent/AU2020202181B2/en not_active Ceased
- 2020-08-12 IL IL276677A patent/IL276677B/en active IP Right Grant
- 2020-09-16 JP JP2020155460A patent/JP6942853B2/ja active Active
-
2021
- 2021-02-10 US US17/248,832 patent/US11780852B2/en active Active
- 2021-03-22 JP JP2021047526A patent/JP2021098757A/ja not_active Withdrawn
-
2023
- 2023-09-05 US US18/242,434 patent/US12358931B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515581A5 (https=) | ||
| JP2021523225A5 (https=) | ||
| ES2625744T3 (es) | Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso | |
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| KR102629267B1 (ko) | 아폽토시스 신호 조절 키나아제 １ 억제제 및 이의 사용 방법 | |
| CA3142069A1 (en) | Aurora kinase inhibitor and use thereof | |
| JP2008530099A5 (https=) | ||
| JP2021523221A5 (https=) | ||
| JP2020533288A5 (https=) | ||
| JP6444866B2 (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン及びその医薬として許容し得る形態の製造プロセス | |
| JP2019514903A5 (https=) | ||
| EA022964B1 (ru) | Соединения, ингибирующие ферменты гистондеацетилазы, и фармацевтическая композиция, содержащая данные соединения | |
| JP2009515988A5 (https=) | ||
| CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP2017506667A (ja) | ２，４−二置換ベンゼン−１，５−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物 | |
| JP2009524691A5 (https=) | ||
| JP2017508733A5 (https=) | ||
| CA2988373A1 (en) | Nrf2 regulators | |
| JP2020517707A5 (https=) | ||
| JP2021522262A5 (https=) | ||
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| JP2023539275A (ja) | 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
| JP2023511146A (ja) | イソインドリン誘導体、並びにその医薬組成物及び使用 | |
| JP2020516616A5 (https=) |